PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets
12 avr. 2023 17h24 HE
|
PLx Pharma Inc.
SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its...
PLx Pharma Inc. Receives Nasdaq Delisting Notice
11 avr. 2023 16h28 HE
|
PLx Pharma Inc.
SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its...
PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update
10 nov. 2022 17h00 HE
|
PLx Pharma Inc.
- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade...
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update
26 oct. 2022 09h00 HE
|
PLx Pharma Inc.
SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its...
Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels
12 sept. 2022 16h30 HE
|
PLx Pharma Inc.
SPARTA, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its...
Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg
12 août 2022 07h00 HE
|
PLx Pharma Inc.
Results of National Patient Experience Survey Show 95% Satisfaction Rate with VAZALORE 81 mg as Aspirin Therapy Choice FDA-Approved VAZALORE Delivers Fast, Reliable Absorption of Aspirin ...
PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update
12 août 2022 06h50 HE
|
PLx Pharma Inc.
- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total...
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update
27 juil. 2022 08h30 HE
|
PLx Pharma Inc.
SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its...
PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022
01 juin 2022 08h30 HE
|
PLx Pharma Inc.
SPARTA, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its...
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions
20 mai 2022 08h30 HE
|
PLx Pharma Inc.
SPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its...